Zanubrutinib plus obinutuzumab and lenalidomide for first-line follicular lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 2, single-arm trial in a Chinese population testing a chemotherapy-free triple regimen of a BTK inhibitor (zanubrutinib), an anti-CD20 antibody (obinutuzumab), and lenalidomide given as induction followed by maintenance with zanubrutinib and lenalidomide. Participants must have histologically confirmed CD20-positive follicular lymphoma (Grade 1–3A) and meet standard criteria for starting therapy. The study will measure antitumor activity (response rates and durability) and safety to characterize efficacy and tolerability of this combination. Archived or fresh tumor tissue for immunohistochemistry is required and patients will be followed for treatment response and adverse events.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Gender: No restrictions; age ≥18 years.
* Diagnosis: Histologically confirmed CD20-positive follicular lymphoma (FL), Grade 1, 2, or 3A, per 2016 WHO classification. All patients must provide sufficient archived or fresh tumor tissue samples for immunohistochemical (IHC) analysis.
* Disease Stage \& Treatment Need:
* Stage III or IV disease, or Stage II with bulky disease, meeting at least one of the following criteria:
* a) Bulky disease: Lymph node or extranodal (excluding spleen) mass with maximum diameter ≥7 cm.
* b) Local symptoms or organ dysfunction due to progressive lymphadenopathy or extranodal tumor mass.
* c) B symptoms (fever, night sweats, or unintentional weight loss \>10% of body weight within ≤6 months).
* d) Symptomatic extranodal involvement (e.g., pleural/peritoneal effusion).
* e) Cytopenias due to bone marrow infiltration (hemoglobin \<10 g/dL, absolute neutrophil count \[ANC\] \<1.0×10⁹/L, platelets \<100×10⁹/L).
* f) Involvement of ≥3 lymph nodes, each ≥3 cm in diameter.
* g) Symptomatic splenomegaly.
* Prior Therapy: No prior systemic therapy for FL.
* ECOG Performance Status: ≤2.
* Measurable Disease: At least one measurable lesion (\>2 cm in longest diameter by CT/MRI).
* Life Expectancy: ≥6 months.
* Adequate Organ Function:
* a) ANC ≥1.0×10⁹/L (without growth factor support).
* b) Platelets ≥50×10⁹/L (untransfused within 7 days).
* c) Total bilirubin (TBIL) ≤1.5×ULN.
* d) ALT/AST ≤3×ULN.
* e) Creatinine clearance ≥30 mL/min (calculated by modified Cockcroft-Gault formula).
* Contraception: Men and women of childbearing potential must agree to use highly effective contraception during the study and for 4 weeks after treatment discontinuation.
* Informed Consent: Patients must voluntarily participate and sign informed consent forms (ICF).

Exclusion Criteria:

* Patients meeting any of the following criteria will be excluded from this study:
* Histologic evidence of central nervous system (CNS) lymphoma, leptomeningeal lymphoma, or transformation to high-grade lymphoma (e.g., diffuse large B-cell lymphoma, DLBCL).
* Grade 3B follicular lymphoma (FL) or transformed FL.
* Ann Arbor Stage I FL.
* Prior history of malignancy, unless the patient has been disease-free for ≥5 years and the treating physician deems the risk of recurrence low (exceptions: non-melanoma skin cancer, cured localized prostate cancer, carcinoma in situ of the cervix, or squamous intraepithelial lesions on PAP smear).
* Use of any investigational drugs, antibiotics, or participation in another interventional clinical trial within 4 weeks prior to enrollment.
* Major surgery (excluding lymph node biopsy) within 14 days before enrollment or anticipated need for major surgery during the study.
* Prior treatment with zanubrutinib, obinutuzumab, or lenalidomide.
* Immunodeficiency or autoimmune disease history, or chronic systemic steroid therapy (\>10 mg/day prednisone equivalent) or immunosuppressive therapy within 7 days before enrollment.
* Severe hepatic dysfunction (including severe jaundice, hepatic encephalopathy, refractory ascites, or hepatorenal syndrome), cachexia, or multi-organ failure with renal impairment.
* Clinically significant cardiovascular abnormalities:
* NYHA Class III/IV heart failure
* Myocardial infarction within 6 months before enrollment, Malignant arrhythmias (including QTc ≥480 ms), Uncontrolled hypertension (Systolic blood pressure (SBP) ≥150 mmHg and diastolic blood pressure (DBP) ≥100 mmHg), Unstable angina.

Active infections:

* HIV, active hepatitis B/C infection (HBV DNA ≥2000 IU/mL or HCV RNA detectable)
* Uncontrolled systemic infections.
* Bleeding disorders or coagulation abnormalities, or thrombotic events within 3 months.
* Severe hypersensitivity to the active ingredients or excipients of the study drugs.
* Pregnancy, lactation, or unwillingness to use effective contraception in women of childbearing potential.
* Other conditions deemed unsuitable by the investigator.

Where it's running

• Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences
  Tianjin, Tianjin Municipality, China Recruiting
• Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences, Tianjin, Tianjin 300020
  Tianjin, Tianjin Municipality, China Not yet recruiting

Study contacts

• Principal investigator: Shuhua Yi — Institute of Hematology & Blood Diseases Hospital, China
• Study coordinator: Shuhua Yi, Dr
• Email: yishuhua@ihcams.ac.cn
• Phone: +86-022-23909106

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Fixed-duration zanubrutinib plus bendamustine and obinutuzumab for newly diagnosed advanced follicular lymphoma

  This tests a six-cycle combination of zanubrutinib, bendamustine, and obinutuzumab for adults with newly diagnosed advanced-stage follicular lymphoma.

  Recruiting The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07126678

• Combining Zanubrutinib and Obinutuzumab for Treating Newly Diagnosed Follicular Lymphoma

  This study is testing a new combination of two medications, Zanubrutinib and Obinutuzumab, to see if they can help people with newly diagnosed follicular lymphoma feel better and stay healthy.

  Recruiting Phase 2 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT06553352

• ZGR: zanubrutinib plus obinutuzumab and lenalidomide for newly diagnosed splenic B‑cell lymphoma with prominent nucleoli

  This trial tries the ZGR combination (zanubrutinib, obinutuzumab, and lenalidomide) as first‑line treatment for people with newly diagnosed SBLPN to see if it is effective and well tolerated.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07165769

• Zanubrutinib, obinutuzumab, and sonrotoclax for newly diagnosed CLL or SLL

  This trial tests whether the three‑drug combination of zanubrutinib, obinutuzumab, and sonrotoclax can produce undetectable measurable residual disease (uMRD) in people with previously untreated CLL or SLL.

  Recruiting at 2 sites Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 1 other locations · NCT06849713

• Combination treatment for relapsed or refractory follicular lymphoma

  This study is testing a new combination of three medications to see if it can help people with relapsed or refractory follicular lymphoma feel better.

  Recruiting at 3 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT06563596

• Combining zanubrutinib and obinutuzumab for untreated chronic lymphocytic leukemia or small lymphocytic lymphoma

  This study is testing if combining two medications, zanubrutinib and obinutuzumab, can help people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma achieve better treatment results.

  Recruiting at 19 sites Phase 2 PETHEMA Foundation · Alicante and 18 other locations · NCT06544785

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.